Editas Medicine (NASDAQ: EDIT) revenue
Editas Medicine reported revenue of $40.5m for fiscal 2025, 25.4% more than in fiscal 2024 ($32.3m). Since fiscal 2016 its revenue has grown by 569.4%, an average growth of 23.5% a year.
Editas Medicine's best year of the last 10 was fiscal 2020. The biggest drop was in fiscal 2021, −71.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $40.5m | +25.4% | −$160.0m | −394.9% |
| 2024 | $32.3m | −58.6% | −$251.2m | −777.2% |
| 2023 | $78.1m | +296.3% | −$169.2m | −216.6% |
| 2022 | $19.7m | −22.8% | −$226.0m | −1,146.3% |
| 2021 | $25.5m | −71.8% | −$193.1m | −756.1% |
| 2020 | $90.7m | +341.9% | −$134.8m | −148.6% |
| 2019 | $20.5m | −35.7% | −$140.9m | −686.4% |
| 2018 | $31.9m | +132.6% | −$113.7m | −356.1% |
| 2017 | $13.7m | +126.8% | −$119.9m | −873.6% |
| 2016 | $6.1m | — | −$97.2m | −1,605.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Editas Medicine revenue compared with its sector
By revenue for its latest fiscal year, Editas Medicine ranks 337th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Editas Medicine, 25.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 335th | Coherus Oncology | $42.2m | 59.8% |
| 336th | Koru Medical Systems | $41.1m | 22.2% |
| 337th | Editas Medicine | $40.5m | 25.4% |
| 338th | Alpha Teknova | $40.5m | 7.4% |
| 339th | Voyager Therapeutics | $40.4m | −49.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Editas Medicine
- How much revenue did Editas Medicine make in fiscal 2025?
- Editas Medicine reported revenue of $40.5m for fiscal 2025, compared with $32.3m in fiscal 2024.
- How much has the revenue of Editas Medicine grown?
- Between fiscal 2016 and fiscal 2025 it went from $6.1m to $40.5m: 569.4% more, an average growth of 23.5% a year.
- What was the best year for revenue at Editas Medicine?
- Of its last 10 fiscal years, fiscal 2020, with $90.7m.
- Where does Editas Medicine rank in its sector by revenue?
- It ranks 337th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Editas Medicine come from?
- From the annual report (Form 10-K) that Editas Medicine files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Editas Medicine files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Editas Medicine: the Editas Medicine page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.